Artiva Biotherapeutics appoints former AbbVie SVP Elaine Sorg as Class I director

Artiva Biotherapeutics, Inc.

Elaine Sorg appointed as Class I director on Feb 18, 2026, term expiring at 2028 annual meeting.
No arrangements or transactions requiring disclosure under Item 404(a) were identified.
Compensation includes $40k annual cash retainer and initial option for 27,500 shares; one-third vests immediately, remainder monthly over two years.
Automatic annual option grants of 13,750 shares on each annual meeting date vest on one-year anniversary or next annual meeting.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.